Ovid Therapeutics Details 2024 Executive Equity Compensation

TL;DR

**OVID's 2024 proxy statement reveals standard executive equity grants, signaling business as usual; no major red flags, but no catalysts either.**

AI Summary

Ovid Therapeutics Inc.'s DEF 14A filing, dated May 22, 2025, primarily details executive compensation and equity award information for the fiscal year ended December 31, 2024. While specific revenue and net income figures are not explicitly provided in this excerpt, the document focuses on the structure of compensation for both named executive officers (PEO) and non-named executive officers (Non-PEO/NEO). Key business changes and strategic outlook are not detailed in this specific filing, which is a proxy statement. The filing indicates grants of employee stock options to individuals like Margaret Alexander and Jeffrey Rona on July 30, 2024, and to Margaret Alexander again on September 9, 2024. The risk section is not elaborated in this excerpt, but the strategic outlook is implicitly tied to incentivizing leadership through equity. The document outlines adjustments to equity awards, including option and stock awards, for both PEO and Non-PEO/NEO categories for the 2024 fiscal year.

Why It Matters

This DEF 14A filing provides crucial transparency into Ovid Therapeutics' executive compensation practices, particularly regarding equity awards for 2024. For investors, understanding how executives are incentivized through stock options and awards is vital for assessing alignment with shareholder interests and potential dilution. Employees, especially those in leadership, gain insight into the company's compensation philosophy and the value placed on their contributions. In the competitive pharmaceutical industry, attractive compensation packages are essential for retaining top talent, directly impacting Ovid's ability to innovate and compete effectively against larger players. The structure of these awards can signal the company's long-term growth strategy.

Risk Assessment

Risk Level: low — The filing is a routine DEF 14A proxy statement, primarily detailing executive compensation and equity awards for 2024. It does not introduce new operational or financial risks, nor does it indicate any immediate threats to Ovid Therapeutics Inc.'s business model. The information presented is standard for corporate governance disclosures.

Analyst Insight

Investors should review the full DEF 14A to understand the complete compensation packages and voting proposals for the upcoming annual meeting. Pay close attention to the performance metrics tied to executive equity awards to gauge alignment with long-term shareholder value. This filing alone doesn't warrant immediate trading action but provides context for governance and management incentives.

Executive Compensation

Key Numbers

• 2024-12-31 — Fiscal Year End (The period covered by the compensation data in the filing.)
• 2025-05-22 — Filing Date (Date the DEF 14A was officially filed with the SEC.)
• 001-38085 — SEC File Number (Unique identifier for Ovid Therapeutics Inc.'s SEC filings.)
• 1934 Act — SEC Act (The Securities Exchange Act under which the filing is made.)
• 22 — Public Document Count (Number of public documents associated with this filing.)

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant filing the DEF 14A
• Margaret Alexander (person) — Recipient of employee stock options on July 30, 2024, and September 9, 2024
• Jeffrey Rona (person) — Recipient of employee stock options on July 30, 2024
• SEC (regulator) — United States Securities and Exchange Commission
• 0001636651 (company) — Central Index Key (CIK) for Ovid Therapeutics Inc.
• 441 Ninth Avenue, 14th Floor, New York, NY 10001 (company) — Business address of Ovid Therapeutics Inc.
• 212-776-4381 (company) — Business phone number of Ovid Therapeutics Inc.
• December 31, 2024 (date) — Conformed period of report end date
• May 22, 2025 (date) — Filed as of date for the DEF 14A
• Pharmaceutical Preparations (company) — Standard Industrial Classification (SIC) for Ovid Therapeutics Inc.

FAQ

Industry Context

Ovid Therapeutics Inc. operates within the pharmaceutical preparations sector, focusing on the development of novel therapeutics. This industry is characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory oversight from bodies like the FDA. Companies in this space often rely on strategic partnerships and equity-based compensation to attract and retain key scientific and executive talent.

Regulatory Implications

As a pharmaceutical company, Ovid Therapeutics is subject to stringent regulations governing drug development, clinical trials, and marketing. Compliance with FDA guidelines and other health authorities is critical. Changes in regulatory landscapes or failure to meet compliance standards can significantly impact the company's operations and the value of its equity awards.

What Investors Should Do

1. Review executive compensation structure
2. Monitor future filings for financial performance

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the period for which compensation data is reported.
• 2025-05-22: Filing Date — The date the DEF 14A proxy statement was officially submitted to the SEC.
• 2024-07-30: Stock Option Grant — Date when employee stock options were granted to Margaret Alexander and Jeffrey Rona.
• 2024-09-09: Stock Option Grant — Date when additional employee stock options were granted to Margaret Alexander.

Glossary

DEF 14A

A definitive proxy statement filed with the SEC by public companies, typically concerning annual meetings of shareholders, including executive compensation details. (This document is the primary source of information regarding executive compensation and equity awards for Ovid Therapeutics Inc. for the fiscal year 2024.)

PEO

Principal Executive Officer, referring to the highest-ranking executive in a company, typically the CEO. (Used to categorize executive compensation and equity award adjustments for the top executive.)

Non-PEO/NEO

Non-Principal Executive Officer/Named Executive Officer, referring to other key executives in the company who are not the PEO. (Used to categorize executive compensation and equity award adjustments for other named executives.)

Employee Stock Option

A contract that gives an employee the right, but not the obligation, to purchase a company's stock at a predetermined price (the strike price) within a specified period. (Details specific grants of these options to executives, indicating a form of incentive-based compensation.)

Equity Awards Adjustments

Changes made to the value or terms of stock options or other equity-based awards granted to employees. (The filing indicates that such adjustments were made for both PEO and Non-PEO/NEO categories in fiscal year 2024.)

Year-Over-Year Comparison

This filing, a DEF 14A, primarily details executive compensation and equity awards for the fiscal year ending December 31, 2024. Specific year-over-year financial metric comparisons (revenue, net income, margins) are not available within this document. However, the focus on equity grants to key executives like Margaret Alexander and Jeffrey Rona suggests a continued strategy of incentivizing leadership through stock-based compensation, a common practice in the biopharmaceutical industry.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 22, 2025 by Margaret Alexander regarding Ovid Therapeutics Inc. (OVID).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR